Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 179

Similar articles for PubMed (Select 16869740)

1.

Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.

Thomas RK, Greulich H, Yuza Y, Lee JC, Tengs T, Feng W, Chen TH, Nickerson E, Simons J, Egholm M, Rothberg JM, Sellers WR, Meyerson ML.

Cold Spring Harb Symp Quant Biol. 2005;70:73-81.

PMID:
16869740
4.

[Detection of epidermal growth factor receptor mutations in non-small cell lung cancer by real-time PCR using TaqMan-MGB probes].

Zhou CC, Zhou SW, Pan H, Su B, Gao ZQ.

Zhonghua Zhong Liu Za Zhi. 2007 Feb;29(2):119-23. Chinese.

PMID:
17645848
5.

EGFR T790M mutation: a double role in lung cancer cell survival?

Suda K, Onozato R, Yatabe Y, Mitsudomi T.

J Thorac Oncol. 2009 Jan;4(1):1-4. doi: 10.1097/JTO.0b013e3181913c9f. Review.

PMID:
19096299
6.

Resistance to an irreversible epidermal growth factor receptor (EGFR) inhibitor in EGFR-mutant lung cancer reveals novel treatment strategies.

Yu Z, Boggon TJ, Kobayashi S, Jin C, Ma PC, Dowlati A, Kern JA, Tenen DG, Halmos B.

Cancer Res. 2007 Nov 1;67(21):10417-27.

7.

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.

Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG, Ladanyi M, Miller VA, Pao W.

Clin Cancer Res. 2006 Nov 1;12(21):6494-501.

8.

Prognostic and therapeutic implications of EGFR and KRAS mutations in resected lung adenocarcinoma.

Marks JL, Broderick S, Zhou Q, Chitale D, Li AR, Zakowski MF, Kris MG, Rusch VW, Azzoli CG, Seshan VE, Ladanyi M, Pao W.

J Thorac Oncol. 2008 Feb;3(2):111-6. doi: 10.1097/JTO.0b013e318160c607.

PMID:
18303429
9.

EGFR inhibitors: what have we learned from the treatment of lung cancer?

Giaccone G, Rodriguez JA.

Nat Clin Pract Oncol. 2005 Nov;2(11):554-61. Review.

PMID:
16270096
11.

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC.

Linardou H, Dahabreh IJ, Bafaloukos D, Kosmidis P, Murray S.

Nat Rev Clin Oncol. 2009 Jun;6(6):352-66. doi: 10.1038/nrclinonc.2009.62. Review.

PMID:
19483740
12.

EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.

Tang X, Shigematsu H, Bekele BN, Roth JA, Minna JD, Hong WK, Gazdar AF, Wistuba II.

Cancer Res. 2005 Sep 1;65(17):7568-72.

13.

Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.

Wong KK.

Lung Cancer. 2008 Jun;60 Suppl 2:S10-8. doi: 10.1016/S0169-5002(08)70100-4. Review.

PMID:
18513579
14.

Impact of EGFR mutation analysis in non-small cell lung cancer.

Yamamoto H, Toyooka S, Mitsudomi T.

Lung Cancer. 2009 Mar;63(3):315-21. doi: 10.1016/j.lungcan.2008.06.021. Epub 2008 Aug 29. Review.

PMID:
18760859
15.

Cytomorphological correlates of epidermal growth factor receptor mutations in lung carcinoma.

Brachtel EF, Iafrate AJ, Mark EJ, Deshpande V.

Diagn Cytopathol. 2007 May;35(5):257-62.

PMID:
17427221
16.

Reversed mutation rates of KRAS and EGFR genes in adenocarcinoma of the lung in Taiwan and their implications.

Wu CC, Hsu HY, Liu HP, Chang JW, Chen YT, Hsieh WY, Hsieh JJ, Hsieh MS, Chen YR, Huang SF.

Cancer. 2008 Dec 1;113(11):3199-208. doi: 10.1002/cncr.23925.

17.

Epidermal growth factor receptor double activating mutations involving both exons 19 and 21 exist in Chinese non-small cell lung cancer patients.

Zhang GC, Lin JY, Wang Z, Zhou Q, Xu CR, Zhu JQ, Wang K, Yang XN, Chen G, Yang JJ, Huang YJ, Liao RQ, Wu YL.

Clin Oncol (R Coll Radiol). 2007 Sep;19(7):499-506. Epub 2007 May 29.

PMID:
17537621
18.

Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer.

Yang SH, Mechanic LE, Yang P, Landi MT, Bowman ED, Wampfler J, Meerzaman D, Hong KM, Mann F, Dracheva T, Fukuoka J, Travis W, Caporaso NE, Harris CC, Jen J.

Clin Cancer Res. 2005 Mar 15;11(6):2106-10. Erratum in: Clin Cancer Res. 2005 Nov 1;11(21):7960-1.

19.

Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients.

Yung TK, Chan KC, Mok TS, Tong J, To KF, Lo YM.

Clin Cancer Res. 2009 Mar 15;15(6):2076-84. doi: 10.1158/1078-0432.CCR-08-2622. Epub 2009 Mar 10.

20.

A new mechanism for primary resistance to gefitinib in lung adenocarcinoma: the role of a novel G796A mutation in exon 20 of EGFR.

Uramoto H, Uchiumi T, Izumi H, Kohno K, Oyama T, Sugio K, Yasumoto K.

Anticancer Res. 2007 Jul-Aug;27(4B):2297-303. Erratum in: Anticancer Res. 2007 Sep-Oct;27(5b):3667.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk